Altimmune, Inc. (NASDAQ: ALT) is a late-stage clinical biotech company headquartered in Gaithersburg, Maryland, developing pemvidutide (ALT-801), a dual GLP-1/glucagon receptor agonist with a balanced 1:1 mechanism designed for metabolic diseases.